IRF6 PATHWAYS AND GENE TARGETS IN PALATE DEVELOPMENT

味觉发育中的 IRF6 通路和基因靶标

基本信息

  • 批准号:
    7479131
  • 负责人:
  • 金额:
    $ 38.28万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-01 至 2009-07-31
  • 项目状态:
    已结题

项目摘要

The goal of Project 0003 is to discover the genes that contribute to isolated cleft lip and palate, a common disorder with complex etiology. This project will study IRF6, a gene that encodes the transcription factor Interferon Regulatory Factor 6. Mutations in IRF6 cause Van der Woude syndrome (VWS). VWS is an outstanding clinical model for isolated cleft lip and palate because the phenotypes of VWS and isolated cleft lip and palate are similar. It is also an outstanding genetic model, since alleles of IRF6 are highly associated with isolated cleft lip and palate in nine geographically distinct populations. These results prove that IRF6 is a key component of a critical pathway in palate development. In this proposal we use mouse models to identify the IRF6 pathway and other genes therein. There are two main hypotheses, 1) IRF6 is a mediator of Tgfb signaling and 2) IRF6 gene targets are essential for palate development. There are three Specific Aims. Specific Aim 1 will determine which cell-type expresses Irf6 in the palate. This basic information will immediately suggest Irf6 pathways and gene targets. Specific Aim 2 will determine which pathways require Irf6 for palate development. The Tgfb3 signaling pathway is essential for palate development and Tgfb3 is expressed at about the same time and place as Irf6. Knockout mice will be used to test the hypotheses that Tgfb3 is essential for expression of Irf6 in the palate shelves. Specific Aim 3 will use microarray analysis to identify the target genes for Irf6 during palate development. In addition, if Irf6 is a mediator for Tgfb3, then gene expression in the palate will be similar in Tgfb3-/- and Irf6-/- mice. Addressing these aims will advance our understanding of Irf6, a gene that is essential in craniofacial development. Further, the IRF6 pathways and targets, discovered in this proposal, will be assessed for their involvement in cleft lip and palate in Project 0001 and in palate development in Project 0004 and Cores 9003 and 9004. This aggregate knowledge will enhance our ability to determine the causes of, and develop preventive interventions for, orofacial clefts.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BRIAN C SCHUTTE其他文献

BRIAN C SCHUTTE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BRIAN C SCHUTTE', 18)}}的其他基金

IRF6 PATHWAYS AND GENE TARGETS IN PALATE DEVELOPMENT
味觉发育中的 IRF6 通路和基因靶标
  • 批准号:
    7666237
  • 财政年份:
    2008
  • 资助金额:
    $ 38.28万
  • 项目类别:
IRF6 PATHWAYS AND GENE TARGETS IN PALATE DEVELOPMENT
味觉发育中的 IRF6 通路和基因靶标
  • 批准号:
    6845929
  • 财政年份:
    2004
  • 资助金额:
    $ 38.28万
  • 项目类别:
CLONING AND CHARACTERIZATION OF THE VAN DER WOUDE GENE
VAN DER WOUDE 基因的克隆和表征
  • 批准号:
    6651305
  • 财政年份:
    2002
  • 资助金额:
    $ 38.28万
  • 项目类别:
CLONING AND CHARACTERIZATION OF THE VAN DER WOUDE GENE
VAN DER WOUDE 基因的克隆和表征
  • 批准号:
    6617324
  • 财政年份:
    2002
  • 资助金额:
    $ 38.28万
  • 项目类别:
CLONING AND CHARACTERIZATION OF THE VAN DER WOUDE GENE
VAN DER WOUDE 基因的克隆和表征
  • 批准号:
    6379968
  • 财政年份:
    2000
  • 资助金额:
    $ 38.28万
  • 项目类别:
CLONING AND CHARACTERIZATION OF THE VAN DER WOUDE GENE
VAN DER WOUDE 基因的克隆和表征
  • 批准号:
    6027902
  • 财政年份:
    2000
  • 资助金额:
    $ 38.28万
  • 项目类别:
Cloning and characterization of the Van Der Woude gene
Van Der Woude 基因的克隆和表征
  • 批准号:
    7467631
  • 财政年份:
    2000
  • 资助金额:
    $ 38.28万
  • 项目类别:
Cloning and characterization of the Van Der Woude gene
Van Der Woude 基因的克隆和表征
  • 批准号:
    7216257
  • 财政年份:
    2000
  • 资助金额:
    $ 38.28万
  • 项目类别:
Cloning and characterization of the Van Der Woude gene
Van Der Woude 基因的克隆和表征
  • 批准号:
    7413639
  • 财政年份:
    2000
  • 资助金额:
    $ 38.28万
  • 项目类别:
CLONING AND CHARACTERIZATION OF THE VAN DER WOUDE GENE
VAN DER WOUDE 基因的克隆和表征
  • 批准号:
    6523890
  • 财政年份:
    2000
  • 资助金额:
    $ 38.28万
  • 项目类别:

相似国自然基金

基于人诱导多能干细胞技术研究突变等位基因特异性敲除治疗1型和2型长QT综合征
  • 批准号:
    82300353
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
PML等位基因突变介导急性早幼粒细胞白血病患者对三氧化二砷耐药的分子机制研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    24 万元
  • 项目类别:
    青年科学基金项目
p38调控CARD9(S12N)杂合子等位基因表达不平衡导致ABPA发生的机制研究
  • 批准号:
    81901673
  • 批准年份:
    2019
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目
等位基因调控TGM6表达介导巨噬细胞极化在抗结核免疫中的作用与机制研究
  • 批准号:
    81970007
  • 批准年份:
    2019
  • 资助金额:
    56 万元
  • 项目类别:
    面上项目
人类基因组中等位基因在父源和母源的基因组中的特异表达和基因印记
  • 批准号:
    81871168
  • 批准年份:
    2018
  • 资助金额:
    57.0 万元
  • 项目类别:
    面上项目

相似海外基金

Orthogonal CRISPR GEMMs
正交 CRISPR GEMM
  • 批准号:
    10639698
  • 财政年份:
    2023
  • 资助金额:
    $ 38.28万
  • 项目类别:
Effects of Aging on Neuronal Lysosomal Damage Responses Driven by CMT2B-linked Rab7
衰老对 CMT2B 相关 Rab7 驱动的神经元溶酶体损伤反应的影响
  • 批准号:
    10678789
  • 财政年份:
    2023
  • 资助金额:
    $ 38.28万
  • 项目类别:
Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA Replicons
研究 RNA 复制子诱导的 SIV/HIV T 和 B 细胞免疫的保护功效
  • 批准号:
    10673223
  • 财政年份:
    2023
  • 资助金额:
    $ 38.28万
  • 项目类别:
Develop an engineered Cas effector for in vivo cell-targeted delivery in the eye to treat autosomal dominant BEST disease
开发工程化 Cas 效应器,用于眼内体内细胞靶向递送,以治疗常染色体显性 BEST 疾病
  • 批准号:
    10668167
  • 财政年份:
    2023
  • 资助金额:
    $ 38.28万
  • 项目类别:
Exploring the function and shedding of a potential C. elegans Neuregulin
探索潜在的线虫神经调节蛋白的功能和脱落
  • 批准号:
    10629996
  • 财政年份:
    2023
  • 资助金额:
    $ 38.28万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了